nodes	percent_of_prediction	percent_of_DWPC	metapath
Ziprasidone—CYP1A2—Carmustine—lymphatic system cancer	0.108	0.216	CbGbCtD
Ziprasidone—CYP3A5—Teniposide—lymphatic system cancer	0.0973	0.195	CbGbCtD
Ziprasidone—CYP3A7—Vincristine—lymphatic system cancer	0.0624	0.125	CbGbCtD
Ziprasidone—CYP3A7-CYP3A51P—Vincristine—lymphatic system cancer	0.0624	0.125	CbGbCtD
Ziprasidone—CYP3A5—Vincristine—lymphatic system cancer	0.0468	0.094	CbGbCtD
Ziprasidone—CYP3A4—Cytarabine—lymphatic system cancer	0.0385	0.0774	CbGbCtD
Ziprasidone—CYP3A4—Teniposide—lymphatic system cancer	0.0379	0.0762	CbGbCtD
Ziprasidone—CYP3A4—Mitoxantrone—lymphatic system cancer	0.0265	0.0533	CbGbCtD
Ziprasidone—CYP3A4—Vincristine—lymphatic system cancer	0.0183	0.0367	CbGbCtD
Ziprasidone—Leukopenia—Bleomycin—lymphatic system cancer	0.000745	0.00148	CcSEcCtD
Ziprasidone—Cardiac disorder—Vincristine—lymphatic system cancer	0.000739	0.00147	CcSEcCtD
Ziprasidone—Alopecia—Carmustine—lymphatic system cancer	0.000737	0.00147	CcSEcCtD
Ziprasidone—Body temperature increased—Fludarabine—lymphatic system cancer	0.000732	0.00146	CcSEcCtD
Ziprasidone—Mental disorder—Carmustine—lymphatic system cancer	0.000731	0.00146	CcSEcCtD
Ziprasidone—Malnutrition—Carmustine—lymphatic system cancer	0.000726	0.00145	CcSEcCtD
Ziprasidone—Erythema—Carmustine—lymphatic system cancer	0.000726	0.00145	CcSEcCtD
Ziprasidone—Cough—Bleomycin—lymphatic system cancer	0.000726	0.00145	CcSEcCtD
Ziprasidone—Angiopathy—Vincristine—lymphatic system cancer	0.000722	0.00144	CcSEcCtD
Ziprasidone—Diarrhoea—Teniposide—lymphatic system cancer	0.000721	0.00144	CcSEcCtD
Ziprasidone—Mediastinal disorder—Vincristine—lymphatic system cancer	0.000718	0.00143	CcSEcCtD
Ziprasidone—Myalgia—Bleomycin—lymphatic system cancer	0.000708	0.00141	CcSEcCtD
Ziprasidone—Chest pain—Bleomycin—lymphatic system cancer	0.000708	0.00141	CcSEcCtD
Ziprasidone—Alopecia—Vincristine—lymphatic system cancer	0.000704	0.0014	CcSEcCtD
Ziprasidone—Back pain—Carmustine—lymphatic system cancer	0.000702	0.0014	CcSEcCtD
Ziprasidone—Mental disorder—Vincristine—lymphatic system cancer	0.000698	0.00139	CcSEcCtD
Ziprasidone—Chills—Mitoxantrone—lymphatic system cancer	0.000696	0.00139	CcSEcCtD
Ziprasidone—Neoplasm—Methotrexate—lymphatic system cancer	0.000696	0.00139	CcSEcCtD
Ziprasidone—Ecchymosis—Methotrexate—lymphatic system cancer	0.000696	0.00139	CcSEcCtD
Ziprasidone—Urine output increased—Methotrexate—lymphatic system cancer	0.000696	0.00139	CcSEcCtD
Ziprasidone—Arrhythmia—Mitoxantrone—lymphatic system cancer	0.000693	0.00138	CcSEcCtD
Ziprasidone—Gynaecomastia—Methotrexate—lymphatic system cancer	0.000688	0.00137	CcSEcCtD
Ziprasidone—Alopecia—Mitoxantrone—lymphatic system cancer	0.000685	0.00136	CcSEcCtD
Ziprasidone—Confusional state—Bleomycin—lymphatic system cancer	0.000685	0.00136	CcSEcCtD
Ziprasidone—Vision blurred—Carmustine—lymphatic system cancer	0.000684	0.00136	CcSEcCtD
Ziprasidone—Hypersensitivity—Fludarabine—lymphatic system cancer	0.000682	0.00136	CcSEcCtD
Ziprasidone—Tremor—Carmustine—lymphatic system cancer	0.00068	0.00135	CcSEcCtD
Ziprasidone—Erythema—Mitoxantrone—lymphatic system cancer	0.000675	0.00134	CcSEcCtD
Ziprasidone—Infection—Bleomycin—lymphatic system cancer	0.000675	0.00134	CcSEcCtD
Ziprasidone—Anaemia—Carmustine—lymphatic system cancer	0.000671	0.00134	CcSEcCtD
Ziprasidone—Back pain—Vincristine—lymphatic system cancer	0.000671	0.00133	CcSEcCtD
Ziprasidone—Vomiting—Teniposide—lymphatic system cancer	0.00067	0.00133	CcSEcCtD
Ziprasidone—Sepsis—Methotrexate—lymphatic system cancer	0.000668	0.00133	CcSEcCtD
Ziprasidone—Agitation—Carmustine—lymphatic system cancer	0.000667	0.00133	CcSEcCtD
Ziprasidone—Thrombocytopenia—Bleomycin—lymphatic system cancer	0.000665	0.00132	CcSEcCtD
Ziprasidone—Asthenia—Fludarabine—lymphatic system cancer	0.000664	0.00132	CcSEcCtD
Ziprasidone—Rash—Teniposide—lymphatic system cancer	0.000664	0.00132	CcSEcCtD
Ziprasidone—Dermatitis—Teniposide—lymphatic system cancer	0.000664	0.00132	CcSEcCtD
Ziprasidone—Headache—Teniposide—lymphatic system cancer	0.00066	0.00131	CcSEcCtD
Ziprasidone—Lymphadenopathy—Methotrexate—lymphatic system cancer	0.000655	0.0013	CcSEcCtD
Ziprasidone—Back pain—Mitoxantrone—lymphatic system cancer	0.000653	0.0013	CcSEcCtD
Ziprasidone—Leukopenia—Carmustine—lymphatic system cancer	0.00065	0.00129	CcSEcCtD
Ziprasidone—Anorexia—Bleomycin—lymphatic system cancer	0.000647	0.00129	CcSEcCtD
Ziprasidone—Thrombophlebitis—Methotrexate—lymphatic system cancer	0.000645	0.00128	CcSEcCtD
Ziprasidone—Diabetes mellitus—Methotrexate—lymphatic system cancer	0.000642	0.00128	CcSEcCtD
Ziprasidone—Anaemia—Vincristine—lymphatic system cancer	0.000641	0.00128	CcSEcCtD
Ziprasidone—Agitation—Vincristine—lymphatic system cancer	0.000637	0.00127	CcSEcCtD
Ziprasidone—Vision blurred—Mitoxantrone—lymphatic system cancer	0.000636	0.00127	CcSEcCtD
Ziprasidone—Polyuria—Methotrexate—lymphatic system cancer	0.000636	0.00127	CcSEcCtD
Ziprasidone—Hypotension—Bleomycin—lymphatic system cancer	0.000634	0.00126	CcSEcCtD
Ziprasidone—Diarrhoea—Fludarabine—lymphatic system cancer	0.000634	0.00126	CcSEcCtD
Ziprasidone—Hypertension—Carmustine—lymphatic system cancer	0.000627	0.00125	CcSEcCtD
Ziprasidone—Nausea—Teniposide—lymphatic system cancer	0.000626	0.00125	CcSEcCtD
Ziprasidone—Anaemia—Mitoxantrone—lymphatic system cancer	0.000624	0.00124	CcSEcCtD
Ziprasidone—Vertigo—Vincristine—lymphatic system cancer	0.000623	0.00124	CcSEcCtD
Ziprasidone—Leukopenia—Vincristine—lymphatic system cancer	0.00062	0.00124	CcSEcCtD
Ziprasidone—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.000619	0.00123	CcSEcCtD
Ziprasidone—Chest pain—Carmustine—lymphatic system cancer	0.000618	0.00123	CcSEcCtD
Ziprasidone—Myalgia—Carmustine—lymphatic system cancer	0.000618	0.00123	CcSEcCtD
Ziprasidone—Anxiety—Carmustine—lymphatic system cancer	0.000616	0.00123	CcSEcCtD
Ziprasidone—Paraesthesia—Bleomycin—lymphatic system cancer	0.00061	0.00121	CcSEcCtD
Ziprasidone—Dyspnoea—Bleomycin—lymphatic system cancer	0.000605	0.00121	CcSEcCtD
Ziprasidone—Renal failure acute—Methotrexate—lymphatic system cancer	0.000605	0.0012	CcSEcCtD
Ziprasidone—Leukopenia—Mitoxantrone—lymphatic system cancer	0.000604	0.0012	CcSEcCtD
Ziprasidone—Hypertension—Vincristine—lymphatic system cancer	0.000598	0.00119	CcSEcCtD
Ziprasidone—Confusional state—Carmustine—lymphatic system cancer	0.000598	0.00119	CcSEcCtD
Ziprasidone—Dermatitis exfoliative—Methotrexate—lymphatic system cancer	0.000592	0.00118	CcSEcCtD
Ziprasidone—Decreased appetite—Bleomycin—lymphatic system cancer	0.00059	0.00118	CcSEcCtD
Ziprasidone—Myalgia—Vincristine—lymphatic system cancer	0.00059	0.00117	CcSEcCtD
Ziprasidone—Visual disturbance—Methotrexate—lymphatic system cancer	0.000589	0.00117	CcSEcCtD
Ziprasidone—Cough—Mitoxantrone—lymphatic system cancer	0.000589	0.00117	CcSEcCtD
Ziprasidone—Infection—Carmustine—lymphatic system cancer	0.000589	0.00117	CcSEcCtD
Ziprasidone—Vomiting—Fludarabine—lymphatic system cancer	0.000589	0.00117	CcSEcCtD
Ziprasidone—Rash—Fludarabine—lymphatic system cancer	0.000584	0.00116	CcSEcCtD
Ziprasidone—Dermatitis—Fludarabine—lymphatic system cancer	0.000583	0.00116	CcSEcCtD
Ziprasidone—Hypertension—Mitoxantrone—lymphatic system cancer	0.000583	0.00116	CcSEcCtD
Ziprasidone—Thrombocytopenia—Carmustine—lymphatic system cancer	0.00058	0.00116	CcSEcCtD
Ziprasidone—Headache—Fludarabine—lymphatic system cancer	0.00058	0.00115	CcSEcCtD
Ziprasidone—Tachycardia—Carmustine—lymphatic system cancer	0.000578	0.00115	CcSEcCtD
Ziprasidone—Myalgia—Mitoxantrone—lymphatic system cancer	0.000575	0.00114	CcSEcCtD
Ziprasidone—Chest pain—Mitoxantrone—lymphatic system cancer	0.000575	0.00114	CcSEcCtD
Ziprasidone—Arthralgia—Mitoxantrone—lymphatic system cancer	0.000575	0.00114	CcSEcCtD
Ziprasidone—Anxiety—Mitoxantrone—lymphatic system cancer	0.000573	0.00114	CcSEcCtD
Ziprasidone—Lethargy—Methotrexate—lymphatic system cancer	0.00057	0.00113	CcSEcCtD
Ziprasidone—Cerebrovascular accident—Methotrexate—lymphatic system cancer	0.00057	0.00113	CcSEcCtD
Ziprasidone—Anorexia—Carmustine—lymphatic system cancer	0.000565	0.00112	CcSEcCtD
Ziprasidone—Infection—Vincristine—lymphatic system cancer	0.000562	0.00112	CcSEcCtD
Ziprasidone—Feeling abnormal—Bleomycin—lymphatic system cancer	0.000559	0.00111	CcSEcCtD
Ziprasidone—Osteoarthritis—Methotrexate—lymphatic system cancer	0.000559	0.00111	CcSEcCtD
Ziprasidone—Confusional state—Mitoxantrone—lymphatic system cancer	0.000556	0.00111	CcSEcCtD
Ziprasidone—Nervous system disorder—Vincristine—lymphatic system cancer	0.000555	0.0011	CcSEcCtD
Ziprasidone—Thrombocytopenia—Vincristine—lymphatic system cancer	0.000554	0.0011	CcSEcCtD
Ziprasidone—Hypotension—Carmustine—lymphatic system cancer	0.000554	0.0011	CcSEcCtD
Ziprasidone—Nausea—Fludarabine—lymphatic system cancer	0.00055	0.0011	CcSEcCtD
Ziprasidone—Infection—Mitoxantrone—lymphatic system cancer	0.000547	0.00109	CcSEcCtD
Ziprasidone—Hyperhidrosis—Vincristine—lymphatic system cancer	0.000547	0.00109	CcSEcCtD
Ziprasidone—Shock—Mitoxantrone—lymphatic system cancer	0.000542	0.00108	CcSEcCtD
Ziprasidone—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.00054	0.00108	CcSEcCtD
Ziprasidone—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	0.000539	0.00107	CcSEcCtD
Ziprasidone—Urticaria—Bleomycin—lymphatic system cancer	0.000539	0.00107	CcSEcCtD
Ziprasidone—Anorexia—Vincristine—lymphatic system cancer	0.000539	0.00107	CcSEcCtD
Ziprasidone—Tachycardia—Mitoxantrone—lymphatic system cancer	0.000538	0.00107	CcSEcCtD
Ziprasidone—Body temperature increased—Bleomycin—lymphatic system cancer	0.000537	0.00107	CcSEcCtD
Ziprasidone—Insomnia—Carmustine—lymphatic system cancer	0.000536	0.00107	CcSEcCtD
Ziprasidone—Skin disorder—Mitoxantrone—lymphatic system cancer	0.000535	0.00107	CcSEcCtD
Ziprasidone—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.000533	0.00106	CcSEcCtD
Ziprasidone—Paraesthesia—Carmustine—lymphatic system cancer	0.000532	0.00106	CcSEcCtD
Ziprasidone—Hypotension—Vincristine—lymphatic system cancer	0.000529	0.00105	CcSEcCtD
Ziprasidone—Dyspnoea—Carmustine—lymphatic system cancer	0.000528	0.00105	CcSEcCtD
Ziprasidone—Somnolence—Carmustine—lymphatic system cancer	0.000527	0.00105	CcSEcCtD
Ziprasidone—Anorexia—Mitoxantrone—lymphatic system cancer	0.000525	0.00105	CcSEcCtD
Ziprasidone—Ataxia—Methotrexate—lymphatic system cancer	0.000525	0.00105	CcSEcCtD
Ziprasidone—Liver function test abnormal—Methotrexate—lymphatic system cancer	0.000516	0.00103	CcSEcCtD
Ziprasidone—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.000515	0.00103	CcSEcCtD
Ziprasidone—Decreased appetite—Carmustine—lymphatic system cancer	0.000515	0.00103	CcSEcCtD
Ziprasidone—Hypotension—Mitoxantrone—lymphatic system cancer	0.000515	0.00103	CcSEcCtD
Ziprasidone—Insomnia—Vincristine—lymphatic system cancer	0.000512	0.00102	CcSEcCtD
Ziprasidone—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.000512	0.00102	CcSEcCtD
Ziprasidone—Paraesthesia—Vincristine—lymphatic system cancer	0.000508	0.00101	CcSEcCtD
Ziprasidone—Constipation—Carmustine—lymphatic system cancer	0.000507	0.00101	CcSEcCtD
Ziprasidone—Breast disorder—Methotrexate—lymphatic system cancer	0.000505	0.001	CcSEcCtD
Ziprasidone—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.000502	0.000999	CcSEcCtD
Ziprasidone—Hypersensitivity—Bleomycin—lymphatic system cancer	0.0005	0.000996	CcSEcCtD
Ziprasidone—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.000495	0.000985	CcSEcCtD
Ziprasidone—Decreased appetite—Vincristine—lymphatic system cancer	0.000492	0.000979	CcSEcCtD
Ziprasidone—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.000491	0.000978	CcSEcCtD
Ziprasidone—Somnolence—Mitoxantrone—lymphatic system cancer	0.00049	0.000975	CcSEcCtD
Ziprasidone—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.000488	0.000972	CcSEcCtD
Ziprasidone—Feeling abnormal—Carmustine—lymphatic system cancer	0.000488	0.000972	CcSEcCtD
Ziprasidone—Fatigue—Vincristine—lymphatic system cancer	0.000488	0.000971	CcSEcCtD
Ziprasidone—Asthenia—Bleomycin—lymphatic system cancer	0.000487	0.00097	CcSEcCtD
Ziprasidone—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.000485	0.000966	CcSEcCtD
Ziprasidone—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.000485	0.000965	CcSEcCtD
Ziprasidone—Constipation—Vincristine—lymphatic system cancer	0.000484	0.000963	CcSEcCtD
Ziprasidone—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.000479	0.000954	CcSEcCtD
Ziprasidone—Eosinophilia—Methotrexate—lymphatic system cancer	0.000478	0.000952	CcSEcCtD
Ziprasidone—Fatigue—Mitoxantrone—lymphatic system cancer	0.000475	0.000946	CcSEcCtD
Ziprasidone—Constipation—Mitoxantrone—lymphatic system cancer	0.000471	0.000938	CcSEcCtD
Ziprasidone—Abdominal pain—Carmustine—lymphatic system cancer	0.000468	0.000933	CcSEcCtD
Ziprasidone—Body temperature increased—Carmustine—lymphatic system cancer	0.000468	0.000933	CcSEcCtD
Ziprasidone—Abdominal discomfort—Methotrexate—lymphatic system cancer	0.000463	0.000921	CcSEcCtD
Ziprasidone—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.000463	0.000921	CcSEcCtD
Ziprasidone—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.000454	0.000904	CcSEcCtD
Ziprasidone—Dysuria—Methotrexate—lymphatic system cancer	0.000451	0.000899	CcSEcCtD
Ziprasidone—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.000451	0.000897	CcSEcCtD
Ziprasidone—Upper respiratory tract infection—Methotrexate—lymphatic system cancer	0.000449	0.000893	CcSEcCtD
Ziprasidone—Abdominal pain—Vincristine—lymphatic system cancer	0.000447	0.00089	CcSEcCtD
Ziprasidone—Body temperature increased—Vincristine—lymphatic system cancer	0.000447	0.00089	CcSEcCtD
Ziprasidone—Erectile dysfunction—Methotrexate—lymphatic system cancer	0.000445	0.000885	CcSEcCtD
Ziprasidone—Photosensitivity reaction—Methotrexate—lymphatic system cancer	0.000441	0.000877	CcSEcCtD
Ziprasidone—Urticaria—Mitoxantrone—lymphatic system cancer	0.000438	0.000871	CcSEcCtD
Ziprasidone—Hypersensitivity—Carmustine—lymphatic system cancer	0.000437	0.000869	CcSEcCtD
Ziprasidone—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.000436	0.000867	CcSEcCtD
Ziprasidone—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.000436	0.000867	CcSEcCtD
Ziprasidone—Pneumonia—Methotrexate—lymphatic system cancer	0.000433	0.000862	CcSEcCtD
Ziprasidone—Vomiting—Bleomycin—lymphatic system cancer	0.000432	0.000859	CcSEcCtD
Ziprasidone—Infestation NOS—Methotrexate—lymphatic system cancer	0.00043	0.000857	CcSEcCtD
Ziprasidone—Infestation—Methotrexate—lymphatic system cancer	0.00043	0.000857	CcSEcCtD
Ziprasidone—Rash—Bleomycin—lymphatic system cancer	0.000428	0.000852	CcSEcCtD
Ziprasidone—Dermatitis—Bleomycin—lymphatic system cancer	0.000428	0.000852	CcSEcCtD
Ziprasidone—Asthenia—Carmustine—lymphatic system cancer	0.000425	0.000847	CcSEcCtD
Ziprasidone—Renal failure—Methotrexate—lymphatic system cancer	0.000423	0.000842	CcSEcCtD
Ziprasidone—Conjunctivitis—Methotrexate—lymphatic system cancer	0.000418	0.000833	CcSEcCtD
Ziprasidone—Hypersensitivity—Vincristine—lymphatic system cancer	0.000417	0.00083	CcSEcCtD
Ziprasidone—Sweating—Methotrexate—lymphatic system cancer	0.000413	0.000822	CcSEcCtD
Ziprasidone—Haematuria—Methotrexate—lymphatic system cancer	0.00041	0.000817	CcSEcCtD
Ziprasidone—Epistaxis—Methotrexate—lymphatic system cancer	0.000406	0.000808	CcSEcCtD
Ziprasidone—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.000406	0.000808	CcSEcCtD
Ziprasidone—Asthenia—Vincristine—lymphatic system cancer	0.000406	0.000808	CcSEcCtD
Ziprasidone—Diarrhoea—Carmustine—lymphatic system cancer	0.000405	0.000807	CcSEcCtD
Ziprasidone—Nausea—Bleomycin—lymphatic system cancer	0.000403	0.000803	CcSEcCtD
Ziprasidone—Asthenia—Mitoxantrone—lymphatic system cancer	0.000395	0.000787	CcSEcCtD
Ziprasidone—Dizziness—Carmustine—lymphatic system cancer	0.000392	0.00078	CcSEcCtD
Ziprasidone—Haemoglobin—Methotrexate—lymphatic system cancer	0.000388	0.000773	CcSEcCtD
Ziprasidone—Diarrhoea—Vincristine—lymphatic system cancer	0.000387	0.000771	CcSEcCtD
Ziprasidone—Haemorrhage—Methotrexate—lymphatic system cancer	0.000386	0.000769	CcSEcCtD
Ziprasidone—Hepatitis—Methotrexate—lymphatic system cancer	0.000386	0.000769	CcSEcCtD
Ziprasidone—Pharyngitis—Methotrexate—lymphatic system cancer	0.000383	0.000764	CcSEcCtD
Ziprasidone—Urinary tract disorder—Methotrexate—lymphatic system cancer	0.000382	0.00076	CcSEcCtD
Ziprasidone—Urethral disorder—Methotrexate—lymphatic system cancer	0.000379	0.000754	CcSEcCtD
Ziprasidone—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.000377	0.000751	CcSEcCtD
Ziprasidone—Vomiting—Carmustine—lymphatic system cancer	0.000377	0.00075	CcSEcCtD
Ziprasidone—Dizziness—Vincristine—lymphatic system cancer	0.000374	0.000745	CcSEcCtD
Ziprasidone—Rash—Carmustine—lymphatic system cancer	0.000374	0.000744	CcSEcCtD
Ziprasidone—Dermatitis—Carmustine—lymphatic system cancer	0.000373	0.000743	CcSEcCtD
Ziprasidone—Visual impairment—Methotrexate—lymphatic system cancer	0.000372	0.000741	CcSEcCtD
Ziprasidone—Headache—Carmustine—lymphatic system cancer	0.000371	0.000739	CcSEcCtD
Ziprasidone—Eye disorder—Methotrexate—lymphatic system cancer	0.000361	0.000719	CcSEcCtD
Ziprasidone—Tinnitus—Methotrexate—lymphatic system cancer	0.00036	0.000717	CcSEcCtD
Ziprasidone—Vomiting—Vincristine—lymphatic system cancer	0.00036	0.000716	CcSEcCtD
Ziprasidone—Cardiac disorder—Methotrexate—lymphatic system cancer	0.000359	0.000714	CcSEcCtD
Ziprasidone—Rash—Vincristine—lymphatic system cancer	0.000357	0.00071	CcSEcCtD
Ziprasidone—Dermatitis—Vincristine—lymphatic system cancer	0.000356	0.00071	CcSEcCtD
Ziprasidone—Headache—Vincristine—lymphatic system cancer	0.000354	0.000706	CcSEcCtD
Ziprasidone—Nausea—Carmustine—lymphatic system cancer	0.000352	0.000701	CcSEcCtD
Ziprasidone—Angiopathy—Methotrexate—lymphatic system cancer	0.000351	0.000698	CcSEcCtD
Ziprasidone—Vomiting—Mitoxantrone—lymphatic system cancer	0.00035	0.000697	CcSEcCtD
Ziprasidone—Immune system disorder—Methotrexate—lymphatic system cancer	0.000349	0.000695	CcSEcCtD
Ziprasidone—Mediastinal disorder—Methotrexate—lymphatic system cancer	0.000348	0.000693	CcSEcCtD
Ziprasidone—Rash—Mitoxantrone—lymphatic system cancer	0.000347	0.000692	CcSEcCtD
Ziprasidone—Dermatitis—Mitoxantrone—lymphatic system cancer	0.000347	0.000691	CcSEcCtD
Ziprasidone—Chills—Methotrexate—lymphatic system cancer	0.000347	0.00069	CcSEcCtD
Ziprasidone—Headache—Mitoxantrone—lymphatic system cancer	0.000345	0.000687	CcSEcCtD
Ziprasidone—Alopecia—Methotrexate—lymphatic system cancer	0.000341	0.00068	CcSEcCtD
Ziprasidone—Mental disorder—Methotrexate—lymphatic system cancer	0.000339	0.000674	CcSEcCtD
Ziprasidone—Erythema—Methotrexate—lymphatic system cancer	0.000336	0.00067	CcSEcCtD
Ziprasidone—Malnutrition—Methotrexate—lymphatic system cancer	0.000336	0.00067	CcSEcCtD
Ziprasidone—Nausea—Vincristine—lymphatic system cancer	0.000336	0.000669	CcSEcCtD
Ziprasidone—Nausea—Mitoxantrone—lymphatic system cancer	0.000327	0.000652	CcSEcCtD
Ziprasidone—Back pain—Methotrexate—lymphatic system cancer	0.000325	0.000648	CcSEcCtD
Ziprasidone—Vision blurred—Methotrexate—lymphatic system cancer	0.000317	0.000631	CcSEcCtD
Ziprasidone—Anaemia—Methotrexate—lymphatic system cancer	0.000311	0.000619	CcSEcCtD
Ziprasidone—Vertigo—Methotrexate—lymphatic system cancer	0.000302	0.000602	CcSEcCtD
Ziprasidone—Leukopenia—Methotrexate—lymphatic system cancer	0.000301	0.000599	CcSEcCtD
Ziprasidone—Cough—Methotrexate—lymphatic system cancer	0.000294	0.000584	CcSEcCtD
Ziprasidone—Myalgia—Methotrexate—lymphatic system cancer	0.000286	0.00057	CcSEcCtD
Ziprasidone—Chest pain—Methotrexate—lymphatic system cancer	0.000286	0.00057	CcSEcCtD
Ziprasidone—Arthralgia—Methotrexate—lymphatic system cancer	0.000286	0.00057	CcSEcCtD
Ziprasidone—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	0.000284	0.000566	CcSEcCtD
Ziprasidone—Confusional state—Methotrexate—lymphatic system cancer	0.000277	0.000551	CcSEcCtD
Ziprasidone—Infection—Methotrexate—lymphatic system cancer	0.000273	0.000543	CcSEcCtD
Ziprasidone—Nervous system disorder—Methotrexate—lymphatic system cancer	0.000269	0.000536	CcSEcCtD
Ziprasidone—Thrombocytopenia—Methotrexate—lymphatic system cancer	0.000269	0.000535	CcSEcCtD
Ziprasidone—Skin disorder—Methotrexate—lymphatic system cancer	0.000267	0.000531	CcSEcCtD
Ziprasidone—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.000265	0.000528	CcSEcCtD
Ziprasidone—Anorexia—Methotrexate—lymphatic system cancer	0.000262	0.000521	CcSEcCtD
Ziprasidone—Hypotension—Methotrexate—lymphatic system cancer	0.000257	0.000511	CcSEcCtD
Ziprasidone—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.00025	0.000498	CcSEcCtD
Ziprasidone—Insomnia—Methotrexate—lymphatic system cancer	0.000248	0.000494	CcSEcCtD
Ziprasidone—Paraesthesia—Methotrexate—lymphatic system cancer	0.000246	0.000491	CcSEcCtD
Ziprasidone—Dyspnoea—Methotrexate—lymphatic system cancer	0.000245	0.000487	CcSEcCtD
Ziprasidone—Somnolence—Methotrexate—lymphatic system cancer	0.000244	0.000486	CcSEcCtD
Ziprasidone—Dyspepsia—Methotrexate—lymphatic system cancer	0.000242	0.000481	CcSEcCtD
Ziprasidone—Decreased appetite—Methotrexate—lymphatic system cancer	0.000239	0.000475	CcSEcCtD
Ziprasidone—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.000237	0.000472	CcSEcCtD
Ziprasidone—Fatigue—Methotrexate—lymphatic system cancer	0.000237	0.000471	CcSEcCtD
Ziprasidone—Feeling abnormal—Methotrexate—lymphatic system cancer	0.000226	0.00045	CcSEcCtD
Ziprasidone—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.000224	0.000447	CcSEcCtD
Ziprasidone—Urticaria—Methotrexate—lymphatic system cancer	0.000218	0.000434	CcSEcCtD
Ziprasidone—Abdominal pain—Methotrexate—lymphatic system cancer	0.000217	0.000432	CcSEcCtD
Ziprasidone—Body temperature increased—Methotrexate—lymphatic system cancer	0.000217	0.000432	CcSEcCtD
Ziprasidone—Hypersensitivity—Methotrexate—lymphatic system cancer	0.000202	0.000403	CcSEcCtD
Ziprasidone—Asthenia—Methotrexate—lymphatic system cancer	0.000197	0.000392	CcSEcCtD
Ziprasidone—Diarrhoea—Methotrexate—lymphatic system cancer	0.000188	0.000374	CcSEcCtD
Ziprasidone—Dizziness—Methotrexate—lymphatic system cancer	0.000182	0.000361	CcSEcCtD
Ziprasidone—Vomiting—Methotrexate—lymphatic system cancer	0.000175	0.000347	CcSEcCtD
Ziprasidone—Rash—Methotrexate—lymphatic system cancer	0.000173	0.000345	CcSEcCtD
Ziprasidone—Dermatitis—Methotrexate—lymphatic system cancer	0.000173	0.000344	CcSEcCtD
Ziprasidone—Headache—Methotrexate—lymphatic system cancer	0.000172	0.000342	CcSEcCtD
Ziprasidone—Nausea—Methotrexate—lymphatic system cancer	0.000163	0.000325	CcSEcCtD
